Trial site
MVZ-Onkologie Velbert GbR
Velbert, 42551, GermanyNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 22 trials
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- AstraZeneca5 trials
- AstraZeneca AB2 trials
- GlaxoSmithKline2 trials
- BeOne Medicines I GmbH1 trial
- Hoffmann-La Roche1 trial
- and 6 more
Running trials
Recruiting
BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer
NCT07492641· Phase 3· BeOne Medicines I GmbH· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037· Phase 3· AstraZeneca· Source
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· Phase 3· Pfizer· Source
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· Phase 3· AstraZeneca· Source
Recruiting
Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A randomized low-intervention phase II trial of the AIO working groups breast cancer and quality of life
2023-504141-31-00· Phase 2· Institut fuer Klinische Krebsforschung IKF GmbH· Source
Active, not recruiting
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· Phase 3· Olema Pharmaceuticals, Inc.· Source
Active, not recruiting
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· Phase 3· AstraZeneca· Source
Active, not recruiting
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the
Metastatic Setting
2024-516653-44-00· Phase 3· AstraZeneca AB· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error